aminolevulinic acid hydrochloride
ApprovedSmall molecule
aminolevulinic acid hydrochloride is one of 171 small molecule programs targeting Oral leukoplakia. It is currently in Approved.
6
Indications
11
Total Trials
2
Active Trials
170
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
514 competitors in Glioblastoma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Gleevec
NovartisPhase 3
Cymbalta
Alnylam PharmaceuticalsPhase 3
Scemblix
NovartisPhase 3
Lexapro
AbbViePhase 3
aminolevulinic acid hydrochloride
MMayo Clinic
Approved
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Feraheme
AAzurity Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Skin Cancer2 trials
Cheilitis1 trial
Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
Completed·—·Phase 4·NCT02409732·24 enrolled
Head and Neck Tumors1 trial
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
Completed·—·Phase 1·NCT00978081·35 enrolled
5 more indications
Glioblastoma1 trial
Oral leukoplakia1 trial
Efficacy and Safety1 trial
5-aminolevulinic Acid1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMayo Clinic